Atom Bios Limited
Atom Bios has developed the world's first stable 10nm programmable nano-liposome, which is ten times smaller than traditional drug carriers. Our breakthrough addresses the root cause of 90% of drug failures: ineffective delivery.
Our proprietary platform achieves the "Goldilocks Zone",small enough to penetrate the BBB and deep tumor tissues, yet large enough to avoid rapid kidney clearance. With over 24 hours of circulation time and programmable surface ligands for targeted navigation, our technology can "rescue" previously failed drug candidates, saving pharmaceutical companies billions in wasted R&D.
We are initially operating as a tech-driven CDMO, partnering with pharmaceutical companies to perform drug-carrier adaptation, optimization, and preclinical testing. Revenue streams include feasibility study fees, milestone payments, and platform licensing. Backed by an unofficial agreement with Sirnaomics and validated through interviews with global pharma and VC partners, Atom Bios is positioned to unlock an entirely new category of deliverable drugs. Our ultimate ambition: develop the first effective Alzheimer's treatment within five years.
Our proprietary platform achieves the "Goldilocks Zone",small enough to penetrate the BBB and deep tumor tissues, yet large enough to avoid rapid kidney clearance. With over 24 hours of circulation time and programmable surface ligands for targeted navigation, our technology can "rescue" previously failed drug candidates, saving pharmaceutical companies billions in wasted R&D.
We are initially operating as a tech-driven CDMO, partnering with pharmaceutical companies to perform drug-carrier adaptation, optimization, and preclinical testing. Revenue streams include feasibility study fees, milestone payments, and platform licensing. Backed by an unofficial agreement with Sirnaomics and validated through interviews with global pharma and VC partners, Atom Bios is positioned to unlock an entirely new category of deliverable drugs. Our ultimate ambition: develop the first effective Alzheimer's treatment within five years.
Key Team Member(s)
Mr NG Cheuk Hei (Department of Applied Biology and Chemical Technology)
Ms LO Yik Sze (Department of Computing)
Mr TSANG Hin Sing
